Weight Loss and Arthritis: A focus on patient-reported outcomes Save

When we discuss weight with someone living with inflammatory arthritis, what are we hoping to achieve? For the patient, the priority may be less pain, improvement in function and mobility, or being able to manage everyday activities. Changes in the number on the scale make up just one part of the picture.

Obesity is associated with poorer physical function and treatment response in rheumatoid arthritis (RA). The ACR guideline on exercise, rehabilitation and diet supports discussing healthy body weight as part of wider RA care. But what happens to patients’ symptoms when they lose weight after starting GLP-1-based treatment?

An analysis presented by Moura and colleagues at ACR Convergence 2026, abstract 0867, addresses that question in routine rheumatology practice.

What did the study show?

Using the ACR RISE registry, the investigators identified 16,848 patients with RA or psoriatic arthritis (PsA) starting semaglutide or tirzepatide. Patients starting new DMARDs during follow-up were excluded.

The paired weight and RAPID3 analysis included 1,880 patients. At 12 months, mean weight loss was 15.6 pounds (approximately 7.1 kg) and mean RAPID3 improvement was 1.3 points on a 0-30 scale.

After adjustment, each 5% reduction in weight was associated with a 0.30-point RAPID3 improvement (95% CI 0.18-0.42). It was also associated with 14% higher odds of achieving a clinically important improvement (adjusted OR 1.14; 95% CI 1.07-1.21), defined as a reduction of at least 3.5 points.

Associations were strongest for pain and patient global assessment, and were broadly consistent across RA and PsA.

What does a lower RAPID3 mean?

RAPID3 brings together patient-reported physical function, pain and global assessment. It does not include a joint count or an inflammatory marker. A lower score therefore tells us that the patient reports feeling better in themselves, but should not be interpreted as, for example, evidence of less synovitis.

This is important for assessing treatment response. We should check whether inflammation is controlled, as well as whether the patient is feeling and functioning better. Preventing inflammatory joint damage is just one goal of treatment; reducing pain and improving the ability to partake in daily activities are just as important.

The practical message from this work is to consider obesity care within the treatment plan, and during longitudinal assessment of inflammatory disease.

Applications in clinical practice

A discussion around weight should form part of a routine assessment of comorbidities associated with RA, especially given the increased risk of cardiovascular disease in this population. In the UK, the National Institute for Health and Care Excellence (NICE) recommends sensitive, non-judgemental conversations that take account of previous experiences and personal circumstances. This includes understanding practical barriers such as finances, access to services and physical limitations.

It is important to identify the available and appropriate support. Depending on the patient’s needs, it might include a dietitian, tailored physical activity or assessment for obesity medication through an appropriate service. ACR guidance recommends regular exercise in RA, adapted to the individual’s abilities and circumstances. Our role can include helping patients access that support and agreeing who will follow up.

We should also avoid attributing every symptom to weight. NICE explicitly warns against this diagnostic overshadowing. It goes without saying that persistent pain deserves assessment, and active inflammatory arthritis requires treatment.

For someone living with RA or PsA, weight loss may also mean less pain and feeling better day to day. This study adds to existing evidence that conversations about weight should be incorporated into rheumatology care, through shared decision-making and in a sensitive manner. Crucially, we should ensure that such conversations lead to appropriate support and treatment.